Biogen (BIIB) PT Lowered to $340 at Goldman Sachs
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $216.77 +0.06%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 20 | New: 27
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 20 | New: 27
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter lowered the price target on Biogen (NASDAQ: BIIB) to $340.00 (from $393.00) while maintaining a Buy rating.
You May Also Be Interested In
- FTAI Infrastructure (FIP) PT Lowered to $12 at Compass Point
- Biogen to present Phase 2 Alzheimer's drug data at AAIC 2026
- BASF SE (BAS:GR) (BASFY) PT Lowered to EUR44 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
